It's always amazed me adalimumab & abatacept, have very different MOA but similar efficacy in RA - on a population level. Not for individuals, though. Surely we can pick the winners better? Lovely biomarker work from a H2H RCT ABST0244 #ACR22 @RheumNow https://t.co/qVttIZSQtc